



DENNIS LIOTTA

Zirus Science Board

Dennis C. Liotta, PhD. serves on the Scientific Advisory Board of Zirus. Dr. Liotta is a renowned organic and medicinal chemist, and the author of approximately 200 publications and patents. Dr. Liotta's research at Emory University has focused on the discovery and development of novel antiviral and anticancer agents, and he has discovered several drugs to treat HIV and Hepatitis B that have broad clinical utility. As former Vice-President for Research at Emory, Dr. Liotta oversaw all of Emory's technology development initiatives. He has served as a consultant to several major pharmaceutical companies (including Merck, GlaxoSmith-Kline, Burroughs Wellcome, Boehringer Ingelheim, and Johnson & Johnson).

Dr. Dennis Liotta received a BA from Queens College, 1970 and a PhD from The City University of New York in 1974. He was a postdoctoral research fellow at Ohio State University from 1974-1976. He has had tremendous success in the development of clinically useful antiviral drugs. These include emtricitabine (Emtriva, Gilead), registered as a component of combination therapy for HIV and as one component of a fixed-dose two drug combination pill, Truvada and the new 3-in-1 pill Atripla (co-marketed by Gilead and BMS). His discoveries also include lamivudine (Epivir, GlaxoSmithKline), which was approved for treatment of both HIV and Hepatitis B virus infection, and D-D4FC/DPC 817 (Reverset, Pharmasset). Gilead Sciences and Royalty Pharma paid Emory University \$540M in July, 2005 in exchange for extinguishing Gilead's future royalty obligations to Emory on its sales of Emtriva/Truvada. Dr. Liotta received the Biomedical Industry Growth Award from the Georgia Biomedical Partnership (2003), Fellow, Alfred P. Sloan Foundation, 1980-1984; Co-chairman, National Science Foundation Workshop on Reactive Intermediates, 1980-1983; Co-chairman, Gulf Coast Chemistry Conference, 1981-present; Alexander von Humboldt Senior Scientist Fellow, 1994-1996; Director, Drug Discovery Program, Winship Cancer Center, 1994-present; AIDS Study Section, National Institutes of Health, 1995-1998; consultant at several pharmaceutical companies, including Boehringer Ingelheim Pharmaceuticals, Triangle Pharmaceutical, Pharmasset, Atherogenics and the R.W. Johnson Pharmaceutical Research Institute.